Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Allergan Aesthetics Completes Acquisition of Soliton -- Addition of Soliton complements Body Contouring Portfolio with expansion to treat appearance of cellulite -- PR Newswire IRVINE, Calif...
Soliton Reports First Quarter 2021 Results PR Newswire HOUSTON, May 12, 2021 HOUSTON, May 12, 2021 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device...
Allergan Aesthetics to Acquire Soliton, Expanding Body Contouring Portfolio -- Acquisition adds Rapid Acoustic Pulse technology platform for improvement in appearance of cellulite in the buttocks...
Introducing RESONIC™ Soliton, Inc. Rolls Out Its Rapid Acoustic Pulse™ Technology with a Multi-Platform Device Indicated for Tattoo Removal and Cellulite Treatment with First Shipments in June PR...
Soliton to Report First Quarter 2021 Financial Results on May 13, 2021 Conference Call to Discuss Results on May 13, 2021 at 4:30 p.m. ET PR Newswire HOUSTON, May 4, 2021 HOUSTON, May 4, 2021...
Soliton Receives FDA Clearance of Special 510(k) Notification paves way for second quarter commercial launch PR Newswire HOUSTON, April 29, 2021 HOUSTON, April 29, 2021 /PRNewswire/ -- Soliton...
Soliton Announces Oral Presentation at American Society for Laser Medicine and Surgery Virtual Annual Conference PR Newswire HOUSTON, April 27, 2021 HOUSTON, April 27, 2021 /PRNewswire/...
Soliton Provides Special 510(k) and Commercialization Update PR Newswire HOUSTON, April 15, 2021 HOUSTON, April 15, 2021 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the...
Soliton to Participate in Three Upcoming Healthcare Conferences PR Newswire HOUSTON, March 11, 2021 HOUSTON, March 11, 2021 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
